Slide 1: ClearPoint: Precise Neuro Navigation & Therapy
ee f 2s CLEARPOINT PRECISE NEURO NAVIGATION & THERAPY
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS ‘Statements herein concerning MRI laterventions, Ine. (the “Company’) plans, growth and strategies may include Aorward-ooking statements within the context ofthe federal sects laws. Statements regarding the Company's future ‘events, developments and future performance, 2s
Slide 3: Only a fraction of patients with debilitating neurological disorders are treated surgically
Only a fraction of patients with debilitating neurological disorders are being treated surgically today Prevalence of Neurological Disorders 51 Procedures Huntington's Disease @ ALS @ 5 ei nd Essential Tremor @ Tumor Epilepsy © Parkinson's a ¢ ¢ ¢ ¢ ¢ ¢
Slide 4: The Movement to Minimally Invasive Procedures has Happened Everywhere Else in the Body
The Movement to Minimally Invasive Procedures has Happened Everywhere Else in the Body This transition has always had two things in common: + More patients being treated + Procedures enabled by live image guidance
Slide 5: Traditional Stereotactic Neurosurgery is Limited
PRIMARY CHALLENGE Traditional Stereotactic Neurosurgery is Limited The Skull is Not ‘See Through’ , * X-Ray and CT do not show structures of the brain + Large, Metallic Navigation Frames are not compatible inside an MRI Magnet + Surgical Image Guidance in the Operating Room is not live but rather ‘C
Slide 6: Our ClearPoint Neuro Navigation Platform
our ClearPoint’ Neuro Navigation ae Platform An MRI Compatible Navigation System Delivering Live MRI Guidance during the Procedure
Slide 7: Our Solution: Alignment and Insertion
Slide 8: MRIC & ClearPoint: A Proven Platform
MRIC & ClearPoint: A Proven Platform jets: FDA C€ Marked Platforms; Almost 3,000 Procedures Performed to HEADQUARTERS EMPLOYEES Irvine,CA 38 16 sales | 19 production & development = fi 15% 2018 REVENUE —_—_-2019 REVENUE FORECAST $7.4m" $9,5m - 10.5m" Razor / Razorblade model with 80+ % of revenue fr
Slide 9: Broad and Growing User Base of Leading Neurosurgeons
BROAD AND GROWING USER BASE OF LEADING NEUROSURGEONS ClearPoint” is Installed in 58 Top US Hospitals and Growing
Slide 10: Our MRI-guided therapy platform is currently being used to...
Our mri-guided therapy platform is currently being used to... Medtronic Medtronic VISUALASE SIEMENS. BBE sr. jue tcoren Boston, Scienufie rs (@sTemcen, see SSENIE IMRIS ¢ BIUeROCK 6 20:9 uns wurenvewnions. we »
Slide 11: Our platform enables choice of precision-guided therapies and services
Our platform enables choice of precision-guided therapies and services CLEARPOINT Nee eters et httigme Rte KJ (4
Slide 12: Example: The Parkinson's Disease Patient
Example: The Parkinson's Disease Patient Enabling Surgeons to choose the right tool for the right patient
Slide 13: Growth in Case Volume and Revenue
2013 - 2018 Growth in Case Volume, ii i Revenue 2019 Revenue Forecast Range of $9.5 -$10.5 Mas of March 11%, 2018
Slide 14: Four Pillar Growth Strategy
on se A THERAPY Four Pillar Growth Strategy Target Indications of > 150,000 procedures per year represents Potential Addressable Market for MRIC of $18+
Slide 15: Grow Our Core Functional Neurosurgery Business
MRI Grow Our Core Functional Neurosurgery Butiness: Focus on Complex Procedures Where Precision is Paramount eae Key Achievements ClearPoint 2.0 Image Fusion Record Q quarterly case volume (188), and Disposable Revenue Increase to 7 sites using two-a-day procedure workflow, expanding ‘adoption drivi
Slide 16: Become the Premier Partner for Biologics & Drug Delivery
vem 2 ‘RI Become the Premier Partner for Biologics & Drug Delivery: Focused Resources for Branding, Device Development and Dist ep Key Achievements CE Mark for the Smartflow Cannula Signed ‘Blueprint’ agreement with YGR in May 2018 Trained clinical specialists for Voyager \VY-AADC tral support; firs
Slide 17: Expand into Direct Therapy Markets: Achieve Greater Share of Procedure Revenue
Expand into Direct Therapy Markets: Achieve Greater Share of Total Procedure Revenue Key Achievements © Acquired License from CLS for Laser System and Applicators for "Neurosurgery and Spine Indications + Opportunity to fine tune our [Navigations system to work seamlessly wet lse ppestordesien ‘enha
Slide 18: Expand into Direct Therapy Markets: First-in-human case for Neuro-Aspiration System
‘Expand into Direct Therapy Markets: Achieve first-in-human case for our Neuro-Aspiration System eae Key Achievements ‘Achieved FDA Clearance for the PURSUIT™ Neuro Aspiration System in December 2018 Collaboration with Mayo Clinic {Affects 80,000 to 100,000 people in the US each year Thee sites in t
Slide 19: Achieve Global Scale and progress toward profitability
Achieve Global Seale and progress toward profitability Capabilities Established Sales Channel capable of distributing. other surgical products + Signed Non-Neuro Distribution agreement with CLs in 2018, Manufacturing Facility in Irvine capable of producing 5x current demand with existing footprint C
Slide 20: Cash Flow From Operations 2015 - 2018
~ 2015 - 2018 it CashFlowFrom Operations = = ~ ecemgen 2018 $3.1 million qe TTT ob
Slide 21: MRIC Capabilities Executive Summary
MRIC CAPABILITIES te Executive Summary > a € EEad es natnteigy pee \: ‘enabling Precision MRI-Guided Therapies to. single-use, high-margin, fetore ust fe for some othe mast openies ee Q ebitatng dsorders Large, Growing installed basen 8012s eating newer coe us OL) rece votme ns gow © OQ. Afenieesite